BRPI0809655A2 - Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit - Google Patents
Método para tratar uma condição em um mamífero, composição farmacêutica, e, kitInfo
- Publication number
- BRPI0809655A2 BRPI0809655A2 BRPI0809655-4A2A BRPI0809655A BRPI0809655A2 BR PI0809655 A2 BRPI0809655 A2 BR PI0809655A2 BR PI0809655 A BRPI0809655 A BR PI0809655A BR PI0809655 A2 BRPI0809655 A2 BR PI0809655A2
- Authority
- BR
- Brazil
- Prior art keywords
- mammalian
- kit
- treating
- condition
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US91185207P | 2007-04-13 | 2007-04-13 | |
PCT/US2008/004760 WO2008127682A2 (en) | 2007-04-13 | 2008-04-11 | Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0809655A2 true BRPI0809655A2 (pt) | 2014-10-07 |
BRPI0809655B1 BRPI0809655B1 (pt) | 2019-09-10 |
BRPI0809655B8 BRPI0809655B8 (pt) | 2021-05-25 |
Family
ID=39638994
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0809655A BRPI0809655B8 (pt) | 2007-04-13 | 2008-04-11 | uso de um composto e um agente terapêutico,composição farmacêutica,e,kit |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080254036A1 (pt) |
EP (2) | EP2155195B1 (pt) |
JP (2) | JP5469595B2 (pt) |
KR (1) | KR101473207B1 (pt) |
CN (2) | CN103071154A (pt) |
AU (1) | AU2008239659B2 (pt) |
BR (1) | BRPI0809655B8 (pt) |
CA (1) | CA2683793C (pt) |
DO (1) | DOP2009000244A (pt) |
EA (1) | EA020531B1 (pt) |
GT (1) | GT200900260A (pt) |
HK (1) | HK1141230A1 (pt) |
IL (1) | IL201433A (pt) |
MX (1) | MX2009010953A (pt) |
NZ (1) | NZ580162A (pt) |
TN (1) | TN2009000408A1 (pt) |
WO (1) | WO2008127682A2 (pt) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1259485T3 (da) | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamider og beslægtede inhibitorer for faktor Xa |
AU2005257999B2 (en) | 2004-06-18 | 2011-12-08 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
US20090186810A1 (en) * | 2006-03-27 | 2009-07-23 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
EA015942B1 (ru) | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
ES2382055T3 (es) | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa |
AU2008205093A1 (en) * | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
MX2009011755A (es) * | 2007-05-02 | 2010-02-12 | Portola Pharm Inc | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. |
US9427448B2 (en) | 2009-11-11 | 2016-08-30 | The Medicines Company | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
PL2498731T3 (pl) * | 2009-11-11 | 2020-07-13 | Chiesi Farmaceutici S.P.A. | Sposoby leczenia lub zapobiegania zakrzepicy w stencie |
US10376532B2 (en) | 2009-11-11 | 2019-08-13 | Chiesi Farmaceutici, S.P.A. | Methods of treating, reducing the incidence of, and/or preventing ischemic events |
US8742120B2 (en) | 2009-12-17 | 2014-06-03 | Millennium Pharmaceuticals, Inc. | Methods of preparing factor xa inhibitors and salts thereof |
WO2011084519A1 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Methods of synthesizing factor xa inhibitors |
WO2011084652A2 (en) | 2009-12-17 | 2011-07-14 | Millennium Pharmaceuticals, Inc. | Salts and crystalline forms of a factor xa inhibitor |
WO2011076749A2 (en) * | 2009-12-23 | 2011-06-30 | Ratiopharm Gmbh | Solid pharmaceutical dosage form |
US20120052058A1 (en) * | 2010-08-30 | 2012-03-01 | Emory University | Methods of managing the blood coagulation and pharmaceutical compositions related thereto |
TW201240664A (en) * | 2010-09-01 | 2012-10-16 | Portola Pharm Inc | Methods and formulations of treating thrombosis with betrixaban and a P-glycoprotein inhibitor |
TW201221128A (en) | 2010-09-01 | 2012-06-01 | Portola Pharm Inc | Crystalline forms of a factor Xa inhibitor |
US20140346397A1 (en) | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US9200268B2 (en) | 2012-12-27 | 2015-12-01 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
US10603316B2 (en) | 2013-08-21 | 2020-03-31 | Morehouse School Of Medicine | Composition and methods for preventing or reducing the incidence of transient ischemic attacks |
WO2015038968A1 (en) * | 2013-09-13 | 2015-03-19 | The General Hospital Corporation | Activatable fibrin-binding probes |
WO2017091757A1 (en) | 2015-11-24 | 2017-06-01 | Portola Pharmaceuticals, Inc. | Isotopically enriched betrixaban |
WO2017208169A1 (en) * | 2016-06-02 | 2017-12-07 | Dr. Reddy’S Laboratories Limited | Polymorphs of betrixaban & its maleate salt |
US11260071B2 (en) | 2017-06-23 | 2022-03-01 | Chiesi Farmaceutici S.P.A. | Method of preventing of systemic-to-pulmonary-artery shunt thrombosis |
CN112888312A (zh) * | 2018-08-28 | 2021-06-01 | 莫尔豪斯医学院 | 用于预防或降低短暂性脑缺血发作发病率的组合物及方法 |
EP4070658A1 (de) * | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI9520044B (sl) | 1994-04-26 | 2004-08-31 | Aventis Pharmaceuticals Inc. | Inhibitorji Xa faktorja |
ATE259789T1 (de) * | 1998-11-27 | 2004-03-15 | Abbott Gmbh & Co Kg | Substituierte benzimidazole und ihre verwendung als parp inhibitoren |
US6794412B1 (en) * | 1999-03-11 | 2004-09-21 | Bristol-Myers Squibb Pharma Company | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin |
AU780787B2 (en) * | 1999-09-17 | 2005-04-14 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
US6844367B1 (en) * | 1999-09-17 | 2005-01-18 | Millennium Pharmaceuticals, Inc. | Benzamides and related inhibitors of factor Xa |
IL148698A0 (en) * | 1999-09-17 | 2002-09-12 | Cor Therapeutics Inc | INHIBITORS OF FACTOR Xa |
DK1259485T3 (da) * | 2000-02-29 | 2006-04-10 | Millennium Pharm Inc | Benzamider og beslægtede inhibitorer for faktor Xa |
GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
US20040192753A1 (en) | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
US7312043B2 (en) * | 2000-07-10 | 2007-12-25 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
US6511973B2 (en) * | 2000-08-02 | 2003-01-28 | Bristol-Myers Squibb Co. | Lactam inhibitors of FXa and method |
HRP20000765A2 (en) | 2000-11-10 | 2002-06-30 | Pliva D D | Compositions of n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides with increased release |
DE10065475A1 (de) * | 2000-12-28 | 2002-07-18 | Switch Biotech Ag | Verwendung von "intermediate-conductance" Kaliumkanälen und Modulatoren zur Diagnose und Behandlung von Krankheiten mit gestörter Keratinozytenfunktion |
WO2002068587A2 (en) * | 2001-02-07 | 2002-09-06 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel human potassium channel beta-subunit, k+betam3 |
US7312235B2 (en) * | 2001-03-30 | 2007-12-25 | Millennium Pharmaceuticals, Inc. | Benzamide inhibitors of factor Xa |
US20030139374A1 (en) * | 2001-09-27 | 2003-07-24 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coagulation and treatment |
US7030141B2 (en) | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
FR2838057B1 (fr) * | 2002-04-05 | 2005-07-08 | Servier Lab | Nouvelle association d'un antithrombotique et d'aspirine |
AU2003270861A1 (en) * | 2002-10-02 | 2004-04-23 | Bristol-Myers Squibb Company | Novel combination of a factor xa inhibitor and clopidogrel |
US20050089473A1 (en) * | 2003-09-10 | 2005-04-28 | Cedars-Sinai Medical Center | Potassium channel mediated delivery of agents through the blood-brain barrier |
FR2860436B1 (fr) * | 2003-10-03 | 2006-01-20 | Servier Lab | Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire |
WO2005034867A2 (en) * | 2003-10-09 | 2005-04-21 | Millennium Pharmaceuticals, Inc. | Thioether-substituted benzamides as inhibitors of factor xa |
DE102004016845A1 (de) * | 2004-04-07 | 2005-10-27 | Bayer Healthcare Ag | Phenylthioessigsäure-Derivate und ihre Verwendung |
AU2005257999B2 (en) * | 2004-06-18 | 2011-12-08 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
US7696352B2 (en) * | 2004-06-18 | 2010-04-13 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
DE102004046623A1 (de) * | 2004-09-25 | 2006-03-30 | Bayer Healthcare Ag | Neue Pyrimidin-Derivate und ihre Verwendung |
DE102005027150A1 (de) * | 2005-03-12 | 2006-09-28 | Bayer Healthcare Ag | Pyrimidincarbonsäure-Derivate und ihre Verwendung |
EP1908481A1 (en) * | 2005-06-24 | 2008-04-09 | Ono Pharmaceutical Co., Ltd. | Agent for reduction of bleeding in cerebrovascular disorder |
US7598276B2 (en) | 2005-11-08 | 2009-10-06 | Millenium Pharmaceuticals, Inc. | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
US20090186810A1 (en) | 2006-03-27 | 2009-07-23 | Portola Pharmaceuticals, Inc. | Potassium channel modulators and platelet procoagulant activity |
EA015942B1 (ru) | 2006-05-05 | 2011-12-30 | Милленниум Фамэсьютикэлс, Инк. | Замещенные имидазолы, композиция на их основе, способ профилактики или лечения нежелательного тромбообразования с их помощью и способ ингибирования коагуляции образцов крови |
ES2382055T3 (es) * | 2006-11-02 | 2012-06-04 | Millennium Pharmaceuticals, Inc. | Métodos para sintetizar sales farmacéuticas de un inhibidor del factor Xa |
WO2008073670A2 (en) * | 2006-12-08 | 2008-06-19 | Millennium Pharmaceuticals, Inc. | Unit dose formulations and methods of treating thrombosis with an oral factor xa inhibitor |
AU2008205093A1 (en) * | 2007-01-05 | 2008-07-17 | Millennium Pharmaceuticals, Inc. | Factor Xa inhibitors |
MX2009011755A (es) * | 2007-05-02 | 2010-02-12 | Portola Pharm Inc | Terapia de combinacion con un compuesto que actua como un inhibidor del receptor adp de plaquetas. |
-
2008
- 2008-04-11 CN CN2012105706089A patent/CN103071154A/zh active Pending
- 2008-04-11 KR KR1020097023491A patent/KR101473207B1/ko active IP Right Grant
- 2008-04-11 NZ NZ580162A patent/NZ580162A/xx not_active IP Right Cessation
- 2008-04-11 EP EP08742820.7A patent/EP2155195B1/en active Active
- 2008-04-11 CN CN200880019506XA patent/CN101743001B/zh not_active Expired - Fee Related
- 2008-04-11 US US12/101,644 patent/US20080254036A1/en not_active Abandoned
- 2008-04-11 AU AU2008239659A patent/AU2008239659B2/en not_active Ceased
- 2008-04-11 EA EA200970946A patent/EA020531B1/ru not_active IP Right Cessation
- 2008-04-11 WO PCT/US2008/004760 patent/WO2008127682A2/en active Application Filing
- 2008-04-11 EP EP12196044.7A patent/EP2591783A1/en not_active Withdrawn
- 2008-04-11 CA CA2683793A patent/CA2683793C/en not_active Expired - Fee Related
- 2008-04-11 MX MX2009010953A patent/MX2009010953A/es active IP Right Grant
- 2008-04-11 BR BRPI0809655A patent/BRPI0809655B8/pt not_active IP Right Cessation
- 2008-04-11 JP JP2010503078A patent/JP5469595B2/ja not_active Expired - Fee Related
-
2009
- 2009-10-07 GT GT200900260A patent/GT200900260A/es unknown
- 2009-10-09 TN TNP2009000408A patent/TN2009000408A1/fr unknown
- 2009-10-11 IL IL201433A patent/IL201433A/en active IP Right Grant
- 2009-10-12 DO DO2009000244A patent/DOP2009000244A/es unknown
-
2010
- 2010-08-10 HK HK10107664.8A patent/HK1141230A1/xx not_active IP Right Cessation
-
2011
- 2011-08-19 US US13/213,912 patent/US8455440B2/en not_active Expired - Fee Related
-
2013
- 2013-05-08 US US13/889,982 patent/US20130315897A1/en not_active Abandoned
- 2013-06-18 JP JP2013127495A patent/JP2013177459A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0809655A2 (pt) | Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit | |
BRPI0921317A2 (pt) | composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero | |
BRPI0912384A2 (pt) | composição, e, método para preparar uma composição | |
BRPI0911681A2 (pt) | composto, composição farmacêutica, e, método para ativar a via de proteína quinase ativada por 5'-amp em uma célula | |
BRPI0815387A2 (pt) | composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição | |
BR112012008854A2 (pt) | combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano | |
BRPI0908092A2 (pt) | Edulcorante, método para preparar uma composição edulcorante, e, composição edulcorante | |
BRPI0908637A2 (pt) | composto; composição farmacêutica do mesmo e método para inibição de proliferação celular em um indivíduo. | |
BRPI0811589A2 (pt) | Composição farmacêutica e método para tratar câncer | |
BRPI0812851A2 (pt) | Composto, composição farmacêutica, métodos para o tratamento de uma doença e de uma condição em um indivíduo, processo para preparar um composto, e, uso de um composto | |
BRPI0814939A2 (pt) | Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero. | |
BRPI0816097A2 (pt) | composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição. | |
BRPI0811059A2 (pt) | combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação | |
BRPI0814503A2 (pt) | composto, uso de um composto, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente, e para tratar uma doença, e, composição farmacêutica | |
BRPI0810806A2 (pt) | Método para tratar uma lesão cutânea em um indivíduo | |
BRPI0918170A2 (pt) | método, e, composição endurecível | |
BRPI0808163A2 (pt) | Composição para aplicação tópica, métodos para tratar uma condição de superfície em um indivíduo, para preparar uma composição, e para usar o kit, e, kit | |
BRPI0814611A2 (pt) | Composição, processo para preparar uma composição, e, uso de uma composição | |
BRPI0911685A2 (pt) | composto, método para o tratamento de uma doença, uso de um composto, composição farmacêutica, e, kit | |
BRPI0817727A2 (pt) | composição de graxa lubrificante, e, método para preparar uma composição de graxa | |
BRPI0912386A2 (pt) | composto, e, métodos para melhorar memória em um indivíduo e para tratar condições relacionadas a uma quinase | |
BRPI0818762A2 (pt) | Composição de biocamada para a liberação de tramadol e acetaminofeno, uso de uma composição, e, método de tratar um mamífero em necessidade de analgesia | |
BRPI0817396A2 (pt) | Método para tratar deficiência de vitamina b12 num indivíduo e composição farmacêutica para tratar deficiência de vitamina b12 num individuo | |
BRPI0819642A2 (pt) | Método para a formação de uma dentadura para um paciente em uma única visita, e, dentadura | |
FI20070935A (fi) | Koostumus ja menetelmä puun käsittelemiseksi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 10/09/2019, OBSERVADAS AS CONDICOES LEGAIS |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B15V | Prolongation of time limit allowed | ||
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 14A ANUIDADE. |
|
B24J | Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12) |
Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2665 DE 01-02-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |